Monitoring minimal residual disease after lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This study checks whether a special blood/tissue test called MRD (minimal residual disease, meaning tiny leftover cancer signals) can help monitor lung cancer after surgery. It may help doctors spot relapse earlier after your tumor has been fully removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) confirmed by biopsy
- Your cancer stage is I, II, or IIIA and it was considered resectable
- You had complete surgical removal of the tumor with clear margins (no R1 or R2)
- You are at least 18 years old and can sign consent
- Your lung cancer is not mixed with small cell lung cancer
- You have not had another cancer in the past 5 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a test called MRD (tiny remaining cancer after treatment) after surgery for early-stage lung cancer. It aims to understand who is more likely to have the cancer return, which could help guide follow-up care.
This trial tests whether monitoring for minimal residual disease (MRD) after surgery can help guide decisions about additional therapy for stage I non-small cell lung cancer (NSCLC). If you've had surgery to completely remove your cancer and are eligible, you may benefit from a personalized approach to follow-up treatment.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
This study tests whether a simple blood test (liquid biopsy) can help doctors monitor for cancer returning after surgery for early-stage lung cancer. It is for people with non-small cell lung cancer that can be removed with surgery.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
This trial tests if a special blood test (called minimal residual disease testing) can find leftover cancer cells early in people with endometrial or cervical cancer. The goal is to see if this test can detect a return of cancer sooner than standard scans or exams.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.